Capital International Investors Grows Position in CRISPR Therapeutics AG (NASDAQ:CRSP)

Capital International Investors lifted its position in shares of CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) by 10.3% in the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 8,743,523 shares of the company's stock after purchasing an additional 816,789 shares during the quarter. Capital International Investors owned about 10.24% of CRISPR Therapeutics worth $344,145,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also recently bought and sold shares of CRSP. Capital International Sarl grew its stake in CRISPR Therapeutics by 9.6% during the fourth quarter. Capital International Sarl now owns 186,920 shares of the company's stock worth $7,357,000 after buying an additional 16,397 shares during the period. NewEdge Advisors LLC boosted its position in CRISPR Therapeutics by 28.0% during the 4th quarter. NewEdge Advisors LLC now owns 7,420 shares of the company's stock worth $292,000 after purchasing an additional 1,622 shares during the period. Jump Financial LLC increased its holdings in CRISPR Therapeutics by 174.0% in the 4th quarter. Jump Financial LLC now owns 139,280 shares of the company's stock valued at $5,482,000 after purchasing an additional 88,448 shares in the last quarter. Elkhorn Partners Limited Partnership raised its position in CRISPR Therapeutics by 22.6% in the fourth quarter. Elkhorn Partners Limited Partnership now owns 3,800 shares of the company's stock valued at $150,000 after purchasing an additional 700 shares during the period. Finally, Jaffetilchin Investment Partners LLC lifted its stake in shares of CRISPR Therapeutics by 56.9% during the fourth quarter. Jaffetilchin Investment Partners LLC now owns 5,208 shares of the company's stock worth $205,000 after purchasing an additional 1,889 shares in the last quarter. Institutional investors and hedge funds own 69.20% of the company's stock.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on the company. Needham & Company LLC reiterated a "buy" rating and set a $84.00 target price on shares of CRISPR Therapeutics in a report on Wednesday, April 9th. StockNews.com upgraded shares of CRISPR Therapeutics to a "sell" rating in a research note on Friday, March 21st. Cantor Fitzgerald restated a "neutral" rating on shares of CRISPR Therapeutics in a research note on Wednesday, February 19th. Evercore ISI raised shares of CRISPR Therapeutics from an "in-line" rating to an "outperform" rating and lifted their price target for the stock from $60.00 to $99.00 in a research note on Friday, February 14th. Finally, JMP Securities reissued a "market outperform" rating and issued a $86.00 price objective on shares of CRISPR Therapeutics in a research report on Thursday, February 13th. Two research analysts have rated the stock with a sell rating, nine have assigned a hold rating and eleven have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Hold" and an average price target of $73.11.

Insider Activity

In other news, General Counsel James R. Kasinger sold 2,850 shares of the business's stock in a transaction that occurred on Tuesday, March 11th. The stock was sold at an average price of $42.42, for a total transaction of $120,897.00. Following the completion of the transaction, the general counsel now directly owns 77,530 shares in the company, valued at approximately $3,288,822.60. The trade was a 3.55 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Samarth Kulkarni sold 18,360 shares of the firm's stock in a transaction that occurred on Wednesday, February 19th. The shares were sold at an average price of $55.20, for a total value of $1,013,472.00. Following the completion of the sale, the chief executive officer now owns 171,613 shares in the company, valued at approximately $9,473,037.60. This represents a 9.66 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 32,381 shares of company stock valued at $1,608,243. 4.10% of the stock is currently owned by company insiders.

CRISPR Therapeutics Stock Down 0.0 %

CRSP opened at $37.77 on Friday. The company's 50-day moving average price is $40.93 and its 200 day moving average price is $43.76. CRISPR Therapeutics AG has a fifty-two week low of $30.04 and a fifty-two week high of $67.88. The firm has a market cap of $3.24 billion, a price-to-earnings ratio of -8.64 and a beta of 1.85.

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last announced its quarterly earnings results on Tuesday, February 11th. The company reported ($0.44) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.15) by $0.71. CRISPR Therapeutics had a negative return on equity of 18.46% and a negative net margin of 981.54%. Research analysts anticipate that CRISPR Therapeutics AG will post -5.16 earnings per share for the current year.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.

Want to see what other hedge funds are holding CRSP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.